Michael Berger

646 total citations
26 papers, 424 citations indexed

About

Michael Berger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Michael Berger has authored 26 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in Michael Berger's work include HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Michael Berger is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Michael Berger collaborates with scholars based in United States, Switzerland and Germany. Michael Berger's co-authors include Maryam B. Lustberg, Bhuvaneswari Ramaswamy, Robert Wesolowski, Charles L. Shapiro, Ewa Mrózek, Craig Vargo, Rachel M. Layman, Nathan D. Seligson, R. Donald Harvey and Gary Phillips and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Breast Cancer Research.

In The Last Decade

Michael Berger

25 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Berger United States 12 281 124 95 82 47 26 424
K. L. Blackwell United States 7 311 1.1× 103 0.8× 71 0.7× 118 1.4× 93 2.0× 16 438
Gillian Bethune Canada 8 222 0.8× 149 1.2× 119 1.3× 189 2.3× 86 1.8× 18 483
Qiong Zhao China 14 299 1.1× 196 1.6× 82 0.9× 145 1.8× 14 0.3× 28 503
S. Sugarman United States 9 332 1.2× 100 0.8× 50 0.5× 101 1.2× 32 0.7× 16 410
Serena Ricciardi Italy 11 342 1.2× 287 2.3× 59 0.6× 178 2.2× 30 0.6× 27 545
George Orphanos Greece 10 225 0.8× 99 0.8× 34 0.4× 107 1.3× 25 0.5× 18 440
Karel Cwiertka Czechia 10 247 0.9× 123 1.0× 108 1.1× 115 1.4× 40 0.9× 45 436
EE Lower United States 6 390 1.4× 191 1.5× 164 1.7× 87 1.1× 13 0.3× 7 603
Yongshuai Jiang China 5 295 1.0× 79 0.6× 54 0.6× 179 2.2× 23 0.5× 7 520

Countries citing papers authored by Michael Berger

Since Specialization
Citations

This map shows the geographic impact of Michael Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Berger more than expected).

Fields of papers citing papers by Michael Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Berger. The network helps show where Michael Berger may publish in the future.

Co-authorship network of co-authors of Michael Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Berger. A scholar is included among the top collaborators of Michael Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Berger. Michael Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldstein, Daniel A., Dionisia Quiroga, Mahmoud Kassem, et al.. (2023). The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Oncology and Therapy. 11(3). 361–374. 1 indexed citations
2.
Berger, Michael, et al.. (2023). Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer. Clinical Breast Cancer. 23(6). 658–663. 8 indexed citations
3.
4.
Berger, Michael, et al.. (2021). Comparison of subsequent infusion hypersensitivity reactions to paclitaxel using two different infusion strategies. Supportive Care in Cancer. 29(8). 4423–4429. 3 indexed citations
5.
Palettas, Marilly, Julie Stephens, Michael Berger, et al.. (2020). Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience. Investigational New Drugs. 38(5). 1605–1611. 2 indexed citations
6.
Berger, Michael, Craig Vargo, Junan Li, et al.. (2019). Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience. Journal of Oncology Pharmacy Practice. 26(3). 572–579. 4 indexed citations
7.
Berger, Michael, Maryam B. Lustberg, Raquel E. Reinbolt, et al.. (2019). Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 20(1). 33–40. 35 indexed citations
8.
Berger, Michael, et al.. (2018). Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer. Journal of Oncology Pharmacy Practice. 25(6). 1374–1380. 2 indexed citations
9.
Vargo, Craig, Michael Berger, Gary Phillips, & Ewa Mrózek. (2016). Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer. Supportive Care in Cancer. 24(7). 2913–8. 3 indexed citations
10.
Wesolowski, Robert, et al.. (2015). Palbociclib. Annals of Pharmacotherapy. 49(11). 1252–1260. 34 indexed citations
11.
Berger, Michael, Craig Vargo, Gary Phillips, et al.. (2014). Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care in Cancer. 23(7). 2019–2024. 19 indexed citations
12.
Reinbolt, Raquel E., et al.. (2014). Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. PubMed. 3. 28–32. 11 indexed citations
13.
Berger, Michael, Marlo Blazer, Brooke Crawford, et al.. (2013). Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care in Cancer. 21(10). 2845–2851. 19 indexed citations
14.
Poi, Ming, Michael Berger, Maryam B. Lustberg, et al.. (2013). Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care in Cancer. 21(10). 2679–2686. 29 indexed citations
15.
Lustberg, Maryam B., Shubham Pant, Amy S. Ruppert, et al.. (2012). Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy and Pharmacology. 70(1). 49–56. 19 indexed citations
16.
Berger, Michael, et al.. (2011). Gene expression changes with differentiation of cord blood stem cells to respiratory epithelial cells: a preliminary observation. Stem Cell Research & Therapy. 2(2). 19–19. 5 indexed citations
17.
Berger, Michael, et al.. (2011). Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care in Cancer. 20(9). 1991–1997. 21 indexed citations
18.
Lustberg, Maryam B., Priya Balasubramanian, Jas C. Lang, et al.. (2010). Abstract 3284: Isolation of circulating tumor cells (CTCs) with mesenchymal and stem cell markers in localized and metastatic breast cancer using a novel negative selection enrichment. Cancer Research. 70(8_Supplement). 3284–3284. 1 indexed citations
19.
Li, Quan, Julianna Roddy, & Michael Berger. (2009). Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting. 1. 2 indexed citations
20.
Kanold, J., Nathalie Boiret, Andréï Tchirkov, et al.. (2000). Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells. Annals of Hematology. 79(1). 13–19. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. L. Blackwell Breakdown of academic impact, for papers by Gillian Bethune Breakdown of academic impact, for papers by Qiong Zhao Breakdown of academic impact, for papers by S. Sugarman Breakdown of academic impact, for papers by Serena Ricciardi Breakdown of academic impact, for papers by George Orphanos Breakdown of academic impact, for papers by Karel Cwiertka Breakdown of academic impact, for papers by EE Lower Breakdown of academic impact, for papers by Yongshuai Jiang
Rankless by CCL
2026